These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3003067)

  • 21. Purification of a functional receptor for calcium-channel blockers from rabbit skeletal-muscle microsomes.
    Flockerzi V; Oeken HJ; Hofmann F
    Eur J Biochem; 1986 Nov; 161(1):217-24. PubMed ID: 3023084
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-affinity binding of DTZ323, a novel derivative of diltiazem, to rabbit skeletal muscle L-type Ca++ channels.
    Hagiwara M; Adachi-Akahane S; Nagao T
    J Pharmacol Exp Ther; 1997 Apr; 281(1):173-9. PubMed ID: 9103495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of diltiazem and verapamil on (+)-PN 200-110 binding kinetics in dog cardiac membranes.
    Miwa K; Miyagi Y; Araie E; Sasayama S
    Eur J Pharmacol; 1992 Apr; 214(2-3):127-32. PubMed ID: 1325351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Photoaffinity labeling of the purified skeletal muscle calcium antagonist receptor by a novel benzothiazepine, [3H]azidobutyryl diltiazem.
    Naito K; McKenna E; Schwartz A; Vaghy PL
    J Biol Chem; 1989 Dec; 264(35):21211-4. PubMed ID: 2556399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heparin binds with high affinity to voltage-dependent L-type Ca2+ channels. Evidence for an agonistic action.
    Knaus HG; Scheffauer F; Romanin C; Schindler HG; Glossmann H
    J Biol Chem; 1990 Jul; 265(19):11156-66. PubMed ID: 2162834
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The devapamil-binding site of the purified skeletal muscle receptor for organic-calcium channel blockers is modulated by micromolar and millimolar concentrations of Ca2+.
    Schneider T; Regulla S; Hofmann F
    Eur J Biochem; 1991 Aug; 200(1):245-53. PubMed ID: 1652439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SR 33557, a novel calcium entry blocker. II. Interactions with 1,4-dihydropyridine, phenylalkylamine and benzothiazepine binding sites in rat heart sarcolemmal membranes.
    Nokin P; Clinet M; Beaufort P; Meysmans L; Laruel R; Chatelain P
    J Pharmacol Exp Ther; 1990 Nov; 255(2):600-7. PubMed ID: 2147036
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target size analysis of skeletal muscle Ca2+ channels. Positive allosteric heterotropic regulation by d-cis-diltiazem is associated with apparent channel oligomer dissociation.
    Goll A; Ferry DR; Glossmann H
    FEBS Lett; 1983 Jun; 157(1):63-9. PubMed ID: 6305718
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [3H] verapamil binding sites in skeletal muscle transverse tubule membranes.
    Galizzi JP; Fosset M; Lazdunski M
    Biochem Biophys Res Commun; 1984 Jan; 118(1):239-45. PubMed ID: 6696758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evidence for a distinct Ca2+ antagonist receptor for the novel benzothiazinone compound HOE 166.
    Striessnig J; Meusburger E; Grabner M; Knaus HG; Glossmann H; Kaiser J; Schölkens B; Becker R; Linz W; Henning R
    Naunyn Schmiedebergs Arch Pharmacol; 1988 Mar; 337(3):331-40. PubMed ID: 2839780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors.
    Galizzi JP; Fosset M; Romey G; Laduron P; Lazdunski M
    Proc Natl Acad Sci U S A; 1986 Oct; 83(19):7513-7. PubMed ID: 2429309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification and characterization of the dihydropyridine-binding subunit of the skeletal muscle dihydropyridine receptor.
    Sharp AH; Imagawa T; Leung AT; Campbell KP
    J Biol Chem; 1987 Sep; 262(25):12309-15. PubMed ID: 3040737
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential-dependent allosteric modulation of 1,4-dihydropyridine binding by d-(cis)-diltiazem and (+/-)-verapamil in living cardiac cells.
    Porzig H; Becker C
    Mol Pharmacol; 1988 Aug; 34(2):172-9. PubMed ID: 2457793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The failure of endothelin to displace bound, radioactively-labelled, calcium antagonists (PN 200/110, D888 and diltiazem).
    Gu XH; Liu JJ; Dillon JS; Nayler WG
    Br J Pharmacol; 1989 Feb; 96(2):262-4. PubMed ID: 2538185
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification of the benzothiazepine-binding polypeptide of skeletal muscle calcium channels with (+)-cis-azidodiltiazem and anti-ligand antibodies.
    Striessnig J; Scheffauer F; Mitterdorfer J; Schirmer M; Glossmann H
    J Biol Chem; 1990 Jan; 265(1):363-70. PubMed ID: 2152924
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pharmacology of the calcium channel: evidence for subtypes, multiple drug-receptor sites, channel subunits, and the development of a radioiodinated 1,4-dihydropyridine calcium channel label, [125I]iodipine.
    Glossmann H; Ferry DR; Goll A; Rombusch M
    J Cardiovasc Pharmacol; 1984; 6 Suppl 4():S608-21. PubMed ID: 6083403
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of four diltiazem stereoisomers on binding of d-cis-[3H]diltiazem and (+)-[3H]PN200-110 to rabbit T-tubule calcium channels.
    Ikeda S; Oka J; Nagao T
    Eur J Pharmacol; 1991 Nov; 208(3):199-205. PubMed ID: 1663043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target size analysis and molecular properties of Ca2+ channels labelled with [3H]verapamil.
    Goll A; Ferry DR; Glossmann H
    Eur J Biochem; 1984 May; 141(1):177-86. PubMed ID: 6327306
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Binding of Ca2+ entry blockers to cardiac sarcolemmal membrane vesicles. Characterization of diltiazem-binding sites and their interaction with dihydropyridine and aralkylamine receptors.
    Garcia ML; King VF; Siegl PK; Reuben JP; Kaczorowski GJ
    J Biol Chem; 1986 Jun; 261(18):8146-57. PubMed ID: 2424894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temperature-dependent regulation of d-cis-[3H]diltiazem binding to Ca2+ channels by 1,4-dihydropyridine channel agonists and antagonists.
    Glossmann H; Linn T; Rombusch M; Ferry DR
    FEBS Lett; 1983 Aug; 160(1-2):226-32. PubMed ID: 6309565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.